A phase II study of oral etoposide in elderly patients with small cell lung cancer.
AUTOR(ES)
Smit, E F
RESUMO
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=461991Documentos Relacionados
- Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.
- Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
- A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer
- Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.
